Characteristics and Differences in Mpox Patients with and without HIV Infection: A Retrospective Cross-Sectional Study in Chengdu, China
Bennan Zhao,Qingxiao Liu,Qing Du,Jun Kang,Rong Tang,Yalan Tu,Dafeng Liu
DOI: https://doi.org/10.2147/ijgm.s456198
IF: 2.145
2024-04-08
International Journal of General Medicine
Abstract:Bennan Zhao, 1, &ast Qingxiao Liu, 2, &ast Qing Du, 3 Jun Kang, 1 Rong Tang, 4 Yalan Tu, 5 Dafeng Liu 1 1 The First Ward of Internal Medicine, Public Health Clinical Center of Chengdu, Chengdu, People's Republic of China; 2 Department of Neurology, Hospital of Chengdu University of TCM, Chengdu, People's Republic of China; 3 The Second Ward of ICU, Public Health Clinical Center of Chengdu, Chengdu, People's Republic of China; 4 Department of Integrated Chinese and Western Medicine, Public Health Clinical Center of Chengdu, Chengdu, People's Republic of China; 5 Scientific Research and Teaching Department, Public Health Clinical Center of Chengdu, Chengdu, People's Republic of China &astThese authors contributed equally to this work Correspondence: Dafeng Liu, The First Ward of Internal Medicine, Public Health Clinical Center of Chengdu, Chengdu, People's Republic of China, Tel +86 1 309 449 4836, Email Yalan Tu, Scientific Research and Teaching Department, Public Health Clinical Center of Chengdu, Chengdu, People's Republic of China, Tel +86 1 501 326 6454, Email Purpose: To date, there are few reports about mpox case series in China, and scarce information is available about the in-vivo kinetics of T-cell responses in the early stage of mpox infection. This study aims to investigate the clinical difference among mpox patients with and without human immunodeficiency virus (HIV) infection. Patients and Methods: A total of 56 patients diagnosed with mpox by Chengdu Center for Disease Control and Prevention (CDC) and hospitalized in Public Health Clinical Center of Chengdu were retrospectively included and divided into an HIV-infected group (n=23) and a non-HIV-infected group (n=33). Clinical characteristics and serum chemistry findings of mpox patients were collected in order to analyze the differences between the HIV-infected group and the non-HIV-infected group. Results: Multiple laboratory abnormalities, including elevated C-reactive protein (69.1%), hypocalcemia (50.9%), elevated CD3+CD8+T counts (47.0%) and inverted ratio of CD3+CD4+T to CD3+CD8+T (64.7%) were common in mpox cases. There were statistically significant differences (all P 10 rashes, incidence of proctitis anus and time from rash growth to rash scab shedding between HIV-infected group and non-HIV-infected group. In the early stage of mpox infection, the median of CD3+CD8+T counts in the non-HIV-infected group was significantly higher than that in healthy donors (P< 0.001), and the median of CD3+CD4+T/CD3+CD8+T ratio was significantly lower (P< 0.001). The median of CD3+CD4+T counts in mpox patients co-infected with HIV significantly decreased compared to the pre-infection level (p =0.033). Conclusion: Our study indicates that mpox co-infected with HIV patients have longer lasting rash lesions and a higher incidence of proctitis anus. T-cell responses may be different between HIV-infected and non-HIV-infected individuals in the early stage of mpox infection. Keywords: mpox, HIV, clinical characteristics, complication, T-cell response Mpox (formerly known as monkeypox) is a zoonotic viral disease caused by monkeypox virus (MPXV). The illness is similar to smallpox; it can cause a painful rash and fever, but mpox is characterized by enlarged lymph nodes and a low case fatality rate. 1 Mpox rash usually transforms through a macular, papular, and vesicular phase and disappears after crusting in approximately 3 weeks, 2 most mpox patients fully recover. 3 Testing skin lesion material by polymerase-chain reaction (PCR) is the most commonly used method for laboratory confirmation of mpox. Before 2022, mpox mainly related to Central and West Africa, with few mpox cases occurring outside of Africa, starting in 2003 in the USA. In May 2022, a multi-country outbreak of mpox broke out in non-endemic countries. 4 As October 2023, the current outbreak has come with 91,788 confirmed mpox cases in 116 countries worldwide. 5 Mpox outbreak is mostly affecting young and middle-aged men who have sex with men (MSM) who participate in high-risk sexual behaviors, 5–8 which is typically the case among human immunodeficiency virus (HIV) infected individuals. It is still unclear whether MPXV can spread through semen or vaginal fluids, but studies have reported that, during this mpox epidemic, the prevalence of HIV and other sexually transmitted diseases has also increased. 9 Unfortunately, there is no evidence that a condom may prot -Abstract Truncated-
medicine, general & internal